Background: Candida species have various degrees of susceptibility to common antifungal drugs. The extent of resistance to amphotericin B and fluconazole of Candida glabrata isolates causing candidemia has been reported. Active surveillance may help us to monitor the trend of susceptibility to antifungal drugs and to determine if there is an emerging co-resistance to both drugs of Candida species, specifically, of C. glabrata in Taiwan.
Background
In the past decade, nosocomial yeast infections have increased globally. In Taiwan, the prevalence of nosocomial candidemia increased 16-fold from 1981 through 1993 [1, 2] . In the United States, yeast infections rank as the fourth most common cause of nosocomial bloodstream infection [3, 4] . Furthermore, candidemia contribute considerable mortality (31% to 38%), extend the length of hospital stay [5, 6] , and increase social cost due to lost productivity and disabling complications [7] . Consequently, the Taiwan Surveillance of Antimicrobial Resistance of Yeasts (TSARY) was initiated in 1999 for epidemiological study of yeast infections in Taiwan [8, 9] Candida species have various degrees of susceptibility to common antifungal agents. Candida lusitaniae is less susceptible to amphotericin B [10] while Candida krusei and Candida glabrata are less susceptible to fluconazole than other Candida species [11] [12] [13] [14] . The extent of fluconazole resistance of C. glabrata isolates causing candidemia has been reported throughout the United States [15] . Furthermore, C. glabrata exhibits variable cross-resistance to the other triazoles, such as voriconazole and posaconazole [13, [16] [17] [18] and amphotericin B became the next choice. The aim of this study is to investigate the trend of susceptibility to amphotericin B and fluconazole of Candida species in Taiwan from 1999 to 2002. Especially, we would like to determine if there is an emerging co-resistance to amphotericin B and fluconazole of Candida species, specifically, of C. glabrata, in Taiwan.
Methods

Organisms and media
Yeast isolates were collected from 11 hospitals participating in both TSARY 1999 and TSARY 2002 [9, 19] . Isolates were stored frozen at -70°C in bead containing Microbank cryovials (PRO-LAB Diagnostics, Austin, TX, USA). At the end of the collection period, isolates were kept frozen and transported by an express delivery company to the laboratory at National Health Research Institutes (NHRI) within 24 hours. After their arrival, the isolates were first sub-cultured on to sabouraud dextrose agar (SDA, BBL, Becton Dickinson Cockeysville, MD, USA) to check for purity and identifications. Pure isolates were labeled and stored in vials containing 50% glycerol at -70°C for subsequent analyses.
Identification
The identification procedure of yeast isolates in the NHRI laboratory was performed as described previously [8] . In general, isolates identified as C. albicans by hospitals were first subjected to the germ tube assay in brain heart infusion (BHI, BBL) medium containing 10% fetal bovine serum (JR12003, JRH Biosciences, Australia) at 37°C for 2-3 hours [20] . Isolates positive in germ tube assay were checked for growth at 42°C to differentiate C. albicans from C. dubliniensis [21] . The VITEK Yeast Biochemical Card (YBC, bioMerieux, St. Louis, MI, USA) was then used to analyze isolates appearing to be negative by the germ tube assay in the NHRI laboratory and isolates identified as non-albicans Candida species by the hospitals. API-32C (bioMerieux) was used to assess the NHRI result when the VITEK-YBC showed less than 90% confidence.
Antifungal susceptibility testing
The minimum inhibitory concentration (MIC) to amphotericin B or fluconazole of each yeast isolate was determined by in vitro antifungal susceptibility testing according to the guidelines by the Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) [22] . The RPMI medium 1640 (31800-022, Invitrogen Corporation, Carlsbad, CA, USA) was used for dilution. Several strains from American Type Culture Collection, namely, ATCC 14053 C. albicans, ATCC 9003 C. glabrata, ATCC 6258 C. krusei, and ATCC20019 Candida parapsilosis were used as controls. The growth of each isolate was measured by a Spectra MAX Plus (Molecular Devices Cop. Sunnyvale, California, USA) after 48-hour incubation at 35°C. We also measured the MICs of some randomlysampled isolates by Etest (AB Biodisk Solna, Sweden) to confirm our results by microdilution.
The interpretation of MICs was conducted according to the guidelines of the CLSI. The MICs to amphotericin B and fluconazole were defined as the lowest concentration of amphotericin B and fluconazole to reduce the turbidity of cells to greater than 95% and 50%, respectively. For amphotericin B, isolates with MIC м 2 µg/ml were considered to be resistant, whereas those with MIC Ϲ 1 µg/ml were susceptible. For fluconazole, isolates with MIC м 64 µg/ml were considered resistant, while those with MIC Ϲ 8 µg/ml were susceptible. Isolates with MICs between 16 and 32 µg/ml were susceptible-dose dependent. The MICs of 50% and 90% of the total population were defined as MIC 50 and MIC 90 . For any species with less than ten, the MIC 50 and MIC 90 were not showed.
Database and analysis
The database for this study contained the following characteristic information of each submitted isolate: hospital origin, location and type of the hospital, identification and source of the isolate. The statistic significance of the differences in frequencies and proportions was determined by the chi-square test with Yates' correction. A p value of Ϲ 0.05 was considered statistically significant.
Results
Distribution of Candida species
The distribution of Candida species was similar in both surveys. Candida albicans was the most common species consisting 37.7% of the total isolates in the 
Susceptibilities to amphotericin B
The susceptibilities to amphotericin B are shown in Table  1 . A total of 10 isolates (2.2%) were resistant to amphotericin B in the TSARY 2002, whereas only one (0.3%) in the TSARY 1999 (p < 0.05). Of these 11 amphotericin B resistant isolates, 9 were non-albicans Candida species, including 5 C. krusei, 3 C. glabrata, and 1 C. tropicalis. In general, C. krusei was less susceptible to amphotericin B than other species.
Susceptibilities to fluconazole
The susceptibilities to fluconazole of Candida species are shown in Table 2 . In the TSARY 1999, a total of 289 (84.5%), 23 (6.7%), and 30 (8.8%) isolates were susceptible, susceptible-dose dependent, and resistant to fluconazole, respectively, whereas in the TSARY 2002, there were 391 (85.5%), 55 (12%), and 10 (2.2%). The MIC 50 and MIC 90 of these isolates in the TSARY1999 were 2 µg/ ml and 16 µg/ml, respectively, and in the TSARY 2002, they were 1 µg/ml and 16 µg/ml. In the TSARY 1999, 12 (12.2%) C. tropicalis, 9 (11%) C. glabrata, 5 (3.9%) C. 
Discussion
The trend of susceptibilities to antifungal drugs of Candida species from 1999 to 2002 has been determined in this study. As expected, C. krusei had the highest resistance rate to fluconazole among Candida species tested, which is consistent with previous reports [9, 11] . In contrast, all C. parapsilosis isolates were susceptible to fluconazole, which is also consistent with previous reports that C. parapsilosis is the most susceptible species to fluconazole [9, 18, 23, 24] . Though the overall resistance rate to fluconazole has decreased from 8.8% to 2.2%, there were significantly more C. glabrata isolates not susceptible to fluconazole in the TSARY 2002 than that in the TSARY 1999. Overexpression of CgCDR1, CgCDR2, and CgSNQ2-encoded efflux pumps has been shown to be a major mechanism contributing to the drug resistance [25] [26] [27] . It would be interesting to investigate the molecular mechanisms of drug resistance of those clinical resistant isolates.
Recently, triazoles have been developed as the new savior to the issue of drug resistance in Candida infection. Nevertheless, C. glabrata exhibits variable cross-resistance among triazoles [9, 18, 23] . Thus, amphotericin B appears to be the choice for treating systemic infections caused by this species. However, along with the increased use of amphotericin B, 20% and 36% of C. glabrata isolates from North America and Latin America, respectively, were reported to be resistant [23] . These data suggest that coresistance to amphotericin B and fluconazole of C. glabrata species may become a problem for clinical therapy worldwide. In our study, we found only three C. glabrata isolates resistant to amphotericin B, which is lower than what has been reported. In that study, 20% of C. glabrata causing candidemia collected in Taiwan in 2003 were resistant to amphotericin B [16] . Coincidently, more C. glabrata isolates in the TSARY 2002 (78.9%) had the MICs of amphotericin B at 1 µg/ml than that in the TSARY 1999 (30.5%). Hence, periodic surveillance is needed to closely monitor the trends of susceptibility to antifungal drugs and for early detection of the newly emerging co-resistance to amphotericin B and fluconazole of Candida species, especially, of C. glabrata. 
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